BTBD7: A Promising Drug Target for Various Diseases (G55727)

Target Name: BTBD7

NCBI ID: G55727

BTBD7

BTBD7: A Promising Drug Target for Various Diseases

BTBD7 (DKFZp686N0544) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the BTBD7 family, which is known for its role in regulating inflammation and autophagy.

Recent studies have suggested that BTBD7 may have potential as a drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because BTBD7 has been shown to play a role in the regulation of cellular processes that are important for the development and progression of these diseases.

One of the key functions of BTBD7 is its role in the regulation of autophagy, a process by which cells break down and recycle damaged or unnecessary proteins. This is important because the regulation of autophagy is involved in a wide range of cellular processes, including the development and progression of cancer, neurodegenerative diseases, and autoimmune disorders.

For example, studies have shown that BTBD7 plays a role in the regulation of autophagy in the brain, which is important for the development and progression of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. This is because BTBD7 has been shown to interact with the protein synuclein, which is also involved in the regulation of autophagy in the brain.

Another function of BTBD7 is its role in the regulation of inflammation. This is important because inflammation is involved in the development and progression of many diseases, including cancer and neurodegenerative diseases.

Studies have shown that BTBD7 plays a role in the regulation of inflammation in various tissues, including the brain, heart, and kidneys. This is because BTBD7 has been shown to interact with the protein NF-kappa-B, which is involved in the regulation of inflammation.

In addition to its role in the regulation of autophagy and inflammation, BTBD7 has also been shown to play a role in the regulation of cellular processes that are important for the development and progression of cancer. This is because BTBD7 has been shown to interact with the protein TGF-β, which is involved in the regulation of cell growth and differentiation.

Given its involvement in the regulation of autophagy, inflammation, and cellular processes that are important for the development and progression of many diseases, BTBD7 is a promising drug target for a variety of conditions. This is because it is possible to target BTBD7 with small molecules or other therapeutic agents that can modulate its activity.

In conclusion, BTBD7 is a protein that is expressed in various tissues of the body and is involved in the regulation of autophagy, inflammation, and cellular processes that are important for the development and progression of many diseases. As a drug target, BTBD7 has the potential to be used to treat a variety of conditions, including cancer, neurodegenerative diseases, and autoimmune disorders.

Protein Name: BTB Domain Containing 7

Functions: Acts as a mediator of epithelial dynamics and organ branching by promoting cleft progression. Induced following accumulation of fibronectin in forming clefts, leading to local expression of the cell-scattering SNAIL2 and suppression of E-cadherin levels, thereby altering cell morphology and reducing cell-cell adhesion. This stimulates cell separation at the base of forming clefts by local, dynamic intercellular gap formation and promotes cleft progression (By similarity)

The "BTBD7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BTBD7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets